D-Ribose improves energy and reduces pain in patients with Chronic Fatigue Syndrome or Fibromyalgia
D-Ribose is a sugar involved with the creation of energy in the cell and research shows that D-Ribose increases cellular energy production in our skeletal muscles and our heart muscle. In chronic fatigue syndrome (CFS) and fibromyalgia (FMS) there is impairment in energy metabolism in the cell. In this study 41 patients diagnosed with either CFS or FMS were supplemented with D-Ribose, 5 grams 3 times a day for a total of 56 doses (18.67 days). D-Ribose was well tolerated and improved the following 5 categories; greater energy, better nights sleep, improved mental clarity, decreased intensity of pain, improved sense of well-being. The 41 patients state that their health improved in every direction and 66% of the patients said their improvement was significant while on D-Ribose. The average improvement in well-being was 39% and the average increase in energy was a dramatic 45%. The study was published in the November 2006 issue of the journal of Alternative and Complementary Medicine.
D-Ribose improves heart function in patients with ischemic heart disease due to severe coronary artery disease
In patients with coronary artery disease there is a reduced volume of blood that can flow to the heart. These patients suffer with ischemic heart disease (reduced blood flow and therefore oxygen deprivation under stress [e.g. when exercising or climbing stairs] that results in angina (chest pain). After resting, when the supply of oxygen from blood flow somewhat catches up with the needs of the more relaxed heart, the organ will still lack the energy supplying molecule in its cells known as ATP for the next 72 hours.
In this study 20 men with severe coronary artery disease who suffer with ischemia and angina were placed on two treadmill exercise tests until they developed symptoms on two consecutive days to make sure the results were somewhat even. They were then split into two groups, one receiving placebo and the other supplemented with 60 grams of D-Ribose a day (divided into 4 equal servings) for the next 3 days. At this point exercise testing was again performed. The D-Ribose group could walk a significantly greater time/distance before moderate symptoms appeared compared to the placebo group. D-Ribose improved the hearts tolerance to ischemia increasing the length of time before experiencing angina. The study is published in the August 29th, 1992 issue of the Lancet.